• Challenges of aging and the medicalization of society
• What is Inclusive Design and how it relates to pharma packaging
• What previous research says about the use of pharma packaging by patients
• How the pharma industry perceives the challenges to design and innovate in packaging
• Opportunities to address the current challenges in pharma packaging
• Technology and the industry challenge
• The value for stakeholders
• The go-to market
• How success looks
• What steps to consider when going connected OR not
• Breaking down the problem by defining categories of needs for each Stakeholder
• Do you really need a connected device and if so which type?
• Matching solutions to needs to enhance the drug delivery process
• Is it possible to try it out - taking a punt?
• The human factor - just because you make it connected doesn't mean people will use it.
• Overview of the drivers for innovation in smart packaging and connected medical devices
• Current products and processes in the pharma supply chain, current environmental monitoring, packaging etc
• Identification of market failures/opportunities for improvement
• Thought leadership on smart packaging and connected medical devices, how this will provide new solutions and improved outcomes for pharma, the pharma supply chain and patients
• Challenges of managing drug delivery (use steps) from patient and caregiver perspective
• How to identify opportunities to reduce complexity in managing the disease state
• Real world videos documenting patient and caregiver experiences managing treatments for pediatric haemophilia
• Status of Brexit discussions
• Implications for medical device and pharmaceutical companies
• Implications for patients and healthcare professionals
• Practical steps and recommendations
• BEPO(R) technology presentation
• High versatility: key formulation parameters for controlling drug release
• Major advantages versus classical long-acting injectable technologies
• Prospectives in the field of Long Acting formulations of fragile molecules
• ICH Q3D and USP661.1 bring new requirements that could 'shake' the industry if not well prepared
• This regulation destroys the well-worn ‘food contact declarations are enough’
• Packaging supply chain will need to evaluate the impact of the new regulations
• USP661.1 taking full effect in May 2020, you might avoid to be ‘shaken’ into last-minute changes!
• Managing complexity at small scale packaging and single patient packs
• Digitalisation and Industry 4.0 processes as enablers for cost effective packaging
• ICH Q12, Quality and Compliance Management
• Challenges in the development of parenteral containers for ophthalmic applications / intravitreal injections
• Polymer Syringe with plasma deposited barrier coating and silicone-oil free lubricity coating
• EO sterilization study to show no gas migration into drug product
• Low particles
Conference | Session 3: Sustainability and Pharmaceutical Packaging & Devices: from Threats to Actions
• How EPR legislation is evolving in the EU under the Circular Economy package
• How EPR legislation is evolving around the world
• Changes your business may need to make to adapt to the changes
With public awareness increasing regarding the environmental impact of all the products we use, each market segment is having to review how it designs, develops and specifies its platforms to minimise environmental impact. Medicine packaging and devices are no exception to this and this presentation will review the following:
• What are we doing as an industry to minimise the environmental impact of inhaler devices and packaging?
• What are the threats and opportunities?
• Green Guides and Corporate Social Responsibility reporting
• What next?
• Considerations for creating a custom primary package
• Challenges with break-through technologies when bringing to scale.
• Regulatory considerations
• Elements of a successful partnership
While new concepts emerge regularly and can provide break-through results in small batches, leapfrog technologies can be difficult to scale. One root cause to this challenge is the need to fit within legacy systems - especially in manufacturing lines that are expensive to change. Thus can be the challenge with drug delivery - how to develop a new delivery solution that won’t require a pharmaceutical firm to change their manufacturing line - a costly and lengthy process.
Portal’s needle-free injector utilizes a custom primary container (cartridge) with a patented nozzle to contain the pharmaceutical product within the injector device. Portal realized that to achieve speed and efficiency to market they would have to work within the constraints of existing, standard fill lines. The cartridge that Portal needs has several challenging requirements: being compatible with existing standard pharmaceutical product fill lines, use approved materials for biological drugs and achieve extremely tight tolerances for the super-fine needle-free jet injection.
• Range of product failures due to packaging on manufacturer
• Case studies demonstrating improvements with upgraded packaging
• Economic impact of upgraded packaging
Challenges and quality expectations for delivery of injectable drugs are rapidly evolving driven by patient communities, regulatory bodies, health care providers, drug manufacturers and drug developers. Failures of packaging components can have a significant impact on one or all of these communities and that cost can have a far more detrimental impact on manufacturers than the initial cost of upgrading a packaging component.
Furthermore, ensuring reliability of the container closure system becomes even more complex as fill finish processes operate at increasingly higher speeds with increasing levels of automation.
In this talk, we will review the impact of high-performance packaging components from the various viewpoints of the patient, the health professional, and the drug m
• From Big Data to Smart Data: the new challenges at line, plant and corporate level in a serialized world
• Intelligent Thinking: how serialization can provide data-driven actions to improve production and warehouse operations
• Industry 4.0 and the benefits of a comprehensive approach to guarantee the quality, integrity and traceability of medicines, containers and packaging
Corporate scandals such as counterfeiting, contamination and cheap labor exploitation impact patients’ safety in the healthcare and the food and beverage industry, and change consumer behavior across the globe.
Discover the vital role of end-to-end traceability in making a better and intelligent supply chain, from the extraction of raw materials, all the way up to the end user and disposal. Leverage cutting-edge technologies to deliver supply chain security, global visibility and brand protection.
Provide a safe product to guarantee its authenticity, to facilitate return and recall management while creating efficient manufacturing processes. Improve your performance, build lasting and trusting relationships with suppliers and clients, and ensure a more sustainable future thanks to end-to-end traceability.
With this presentation, the audience will understand how end-to-end traceability can help companies gain visibility among their supply chain, increase their performance, improve the safety of their products and ultimately of their customers.
• EU FMD 2019 readiness: have you considered a plan B?
• Learn how to leverage efficiently your serialization data in the supply chain
• Discover how new technologies like Blockchain, Artificial Intelligence and IoT will impact your business for enhanced supply chain security and transparency
Omplementation of an innovative high-speed laser-marking solution on glass prefilled syringes at Sanofi Pasteur. This track and trace solution applies to all types of glass syringes and has the primary objective to drastically enhance mix-up prevention.
Through the case study, the audience will understand how a pharmaceutical company is tackling significant issues such as traceability, container identification and manufacturing flexibility through the implementation of an innovative marking technology.
The audience will get an overview of the key criteria defined by Sanofi Pasteur to select this technology. The audience will also understand how this implementation can be done on high-speed industrial processes through description of the project and the main challenges.
The audience may also better understand the additional benefits this technology could bring such as anti-counterfeiting and supply chain flexibility.
• Shelf-life - Up to 200% longer shelf-life compared to previous solution
• Safety in application - Pre-filled accurate dose, controlled droplet size during spraying, no dripping before and after application
• Handling - Easy, intuitive handling allows healthcare professionals to focus fully on the patient
• Hygiene - Traceable single use device enhances infection control
• Comparison of the three irradiation technologies
• Quality and technical advantages of irradiation with regards to product feasibility
• Case studies
• Multilayer Plastic Vial and Syringe
• Excellent oxygen and UV barrier to prevent oxidation of drugs
• Very low extractables
• Customizable vial and syringe
• Advantages of Drug Repurposing
• Overcoming Challenges
• Successful Transitions
• Regulatory Perspective
• What is the Digital Medicines Eco-system
• Impact on patient health outcomes and the overall healthcare system
• How to build a successful eco-system
• Stakeholder’s perspective
• Elastomeric components are the major contributor to leachables in the drug product
• A migration study was performed to evaluate potential leachables from both steam and gamma irradiated Ready to Use (RTU) and ETFE coated injectable components
• The results from this study, which demonstrated comparability in leachable profiles, will be present
• Assessing user needs in Hyaluronic Acid delivery
• Addressing user needs through an optimal Hyaluronic Acid delivery system
• BD Hylok™: designed to enhance user experience in Hyaluronic Acid delivery
• Speed of innovation • Drug Delivery Devices in a broader smart ecosystem: From Diagnosis to AI
• Which benefits for the patients, pharma, and payers?
• Go to market and business models